This study tries to establish a new method for the evaluation of skin lesion extension and progression in systemic sclerosis (SSc) patients. Plica thickness measurements of 200 healthy subjects and 19 SSc patients by plicometer were performed, and an arbitrary plicometer skin score was created. The plicometer skin score was compared to m-Rodnan's score on the same patients. The statistical association between the plicometer score and DLCO values in SSc patients was analysed. Plicometer plica thickness cut-off values of normality were established for nine skin areas. High specificity (95-99%) and a high negative predictive value (95.5-100%) were found. The sensitivity and the positive predictive value were 52.6-100% and 52.4-90.5%, respectively. The coefficient of variation of the plicometer score (0.05-0.14) was lower than that of the m-Rodnan score (0.22-0.33). A statistically significant association was found between skin score and DLCO. The study underlines the accuracy and reproducibility of the plicometer skin test, and suggests its utility in monitoring scleroderma progression.
S sclerosis (SSc) is a disease of unknown origin characterized by a generalized disorder of connective tissue. Thickening and fibrosis of skin (scleroderma) are the hallmarks of the disease, although, rarely, patients show an absence of apparent skin disease (SSc sine scleroderma) in the presence of typical visceral involvement and serological markers. Two clinical patterns of SSc, diffuse and limited, have been identified on the basis of the extension of cutaneous lesions and of the entity and progression of visceral involvement [1] . In both forms of SSc, the pace, progression and extent of skin lesions parallel the risk of occurrence of new (or of the spreading of) internal organ involvement, which is the main determinant for morbidity and mortality [2] [3] [4] . Thus, it has been postulated that a satisfactory follow-up of disease activity can be achieved by accurately monitoring skin lesions. To this end, a variety of techniques have been employed to indicate skin changes in SSc, including roentgenography, biopsy and clinical palpation [5] . This latter method obtained broad consensus among clinicians for its simplicity, feasibility and patient compliance. To date, the most widely adopted total skin score technique has been Rodnan's which assigns a score (0 = absence, 1 = mild, 2 = moderate, 3 = severe, 4 = extreme skin thickness) to 26 skin areas [6] . However, Rodnan's score and its simplified versions (i.e. m-Rodnan's techniques) [7, 8] fail to reach a high level of reproducibility due to the variable experience of the operators and to the objective difficulty in differentiating skin thickness, tethering and oedema by palpation [2, 5, 9] . To establish a quantitative method (poorly influenced by operator variability) for the study of SSc skin changes, we invented a new skin score method by using a plicometer, an instrument which provides a quantitative value of the thickness of cutaneous plica (the folded part of skin). Plicometer skin values from different cutaneous areas of 200 healthy subjects and of 19 SSc patients were analysed statistically by using Poisson's theorem and a cut-off value (corresponding to the minimum normal value) was derived which clearly differentiates normal skin from SSc skin. On this basis, a new four-class skin score was developed whose sensitivity, specificity and reproducibility are described and compared to the same parameters of the modified Rodnan's (m-Rodnan's) skin score technique.
MATERIALS AND METHODS

Subjects
Two hundred healthy individuals (100 male and 100 female) of age ranging from 20 to 65 yr were included in the study as controls. Nineteen patients (17-65 yr), who met American College of Rheumatology (ACR) criteria for SSc, were also studied at the time of their first admission to our institution. Patients did not consume immunosuppressive drugs before entering into the study. They were further classified as having diffuse (13 patients), limited (three patients) and sine scleroderma (three patients) forms of SSc, and were not receiving steroid therapy at the time of observation. Clinical features of each patient are detailed in Table I .
The study was approved by the ethical committee of the Department of Internal Medicine at the University of Genoa and all participants gave informed written consent.
Plicometer
The plicometer (GIMA-FIT Comp, Italy) is a very precise medical tool which matches international standards (pressure 10 g/mm 2 ) [10] and allows pressure calibration to warrant a constant spring tension over the time, corresponding to 0.098 Newtons/mm 3 . It possesses two arms whose skin contact surfaces are nylon covered; it is provided with two scales, calibrated on a cut-off of 0.2 and 0.5 mm, respectively (Fig. 1A-D) .
Plicometer and m-Rodnan's skin tests
The plicometer is commonly used to measure the s.c. plica in obese individuals. To this end, the instrument is applied to conventional skin areas (corresponding to sites of typical fat distribution in the two genders) pinching both skin and s.c. fat over the muscle. In our study, the measurements of cutaneous plica were performed taking care only to pinch the skin and to avoid capturing s.c. tissue between its arms (identifying a cleavage plane between the two tissues). With this aim, the instrument was gently placed on the skin surface (avoiding any pressure) and the plica was generated (and measured) by the plicometer itself during the closure of the arms. Two measurements were performed in each skin area: if the two values of plica thickness obtained did not differ by more than 5%, then the mean of the two measures was considered. Otherwise, a third measurement was carried out and considered together with the closest of the previous measures. m-Rodnan's skin test was performed as described previously [7] .
Measurements of the cutaneous plica were carried out by using a plicometer in the following nine skin areas: (1) the middle zone of each cheekbone; (2) the middle zone of the manubrium of the sternum; (3) 3 cm above the umbilicus; (4) the middle zone of the dorsal face of both upper arm and (5) forearm; (6) the zone at the base of both third metacarpals on the dorsal face of the hands; (7) the middle zone of the ventral face of both thighs; (8) the middle zone of the dorsal face of either lower leg; and (9) the zone at the base of the first metatarsus of the dorsal face of the foot. The cited skin areas were chosen because they are potential sites of scleroderma involvement and are easily accessible to the plicometer. For symmetrical skin areas, the arithmetical mean of the measurements obtained from both sides was considered.
Creation of an arbitrary plicometer skin score
The severity of sclerodermal skin involvement was evaluated by an arbitrary skin score. We attributed a score of 0 to healthy skin; 1 to skin whose plica measurement fell within a range between 0.2 mm below the cut-off (because the minimum difference measurable by the plicometer is 0.2 mm) and a value corresponding to half of the cut-off; 2 to a cutaneous plica whose thickness value was lower than half of the cut-off; 3 to skin where the plicometer was not able to obtain any plica (Table II) . A plicometer total skin score for each patient was derived by the arithmetical sum of the score obtained in each skin area. The skin score was performed on the bases of plicometer measurements and of the arbitrary skin score detailed in Table II . *f, female; m, male. †D, diffuse SSc; L, limited SSc; S, SSc sine scleroderma. ‡ − , no alterations; + , low reduction of diffusing capacity of carbon monoxide (DLCO) (Q25%) and/or vital capacity (VC) (Q20%); + + , moderate reduction of DLCO (Q45%) and/or VC (Q40%); + + + , severe reduction of DLCO (Q55%) and/or VC (Q50%). § − , no alterations; + , increased resistance in renal arteries; + + , increased resistance in renal arteries and reduced clearance. ¶ − , no alterations, + , right axial deviation; + + , right axial deviation and pericardial effusion. >ANA, antinuclear antibodies; centr, centromeric pattern; nucl, nucleolar pattern; sp, speckled pattern; hom, homogeneous pattern; scl70, anti-scl70 antibodies. **a.s.p., active sclerodermal pattern; s.s.p., slow sclerodermal pattern.
The plicometer while it is pinching the skin of a healthy subject; (B) a close-up of the plicometer arms pinching healthy skin on the arm; (C) the plicometer while it is pinching the skin of a SSc patient; (D) a close-up of the plicometer arms pinching sclerodermal skin on the arm. Note the different thickness of the plicae of healthy and pathological skin, and the corresponding different position of the needle on the plicometer scale.
Evaluation of vital capacity (VC) and diffusing capacity of carbon monoxide (DLCO) of lung
The vital capacity of the lung (maximal expiratory flow after a forced inspiration) was analysed by spirometry; the values were expressed as percentage of VC reduction with respect to a normal standard and a reduction E20% was considered within the normal range [11, 12] .
The evaluation of DLCO was performed by using the steady-state method, as described previously [13] . The values were expressed as percentage of DLCO reduction with respect to a normal standard and a reduction of E25% was considered within the normal range [13] .
Statistical analysis
Since our plicometer skin measurements from healthy subjects were continuous and normally distributed data (as resulted from the calculation of the mean, median and standard deviation [..]), we used Poisson's theorem to calculate the standard error of the mean (...), standard error of the per cent frequency (...), and 95% confidence level, which includes the 95% range of normal s.c. plica values (mean 2 2 ..). We assumed the value of the mean − 2 .. for each cutaneous area (one for male and one for female) as the cut-off dividing healthy from SSc skin.
The distribution of plica thickness values from healthy and SSc individuals with respect to the cut-off was calculated by Fisher's exact test because the sample number was Q2000 and the cases were not paired.
The accuracy indices of the plicometer test (sensitivity, specificity, efficiency, positive predictive value and negative predictive value) were calculated as follows: sensitivity = real positive (RP)/RP + false negative (FN); specificity = real negative (RN)/RN+ false positive (FP); efficiency = RP + RN/RN+ RP + FN + FP; positive predictive value (PPV) = RP/ RP + FP; negative predictive value (NPV) = RN/ RN + FN.
The degree of dispersion of cutaneous plica thickness measures obtained by six observers applying the plicometer test in each considered skin area of six healthy subjects and six SSc patients (of age between 17 and 65 yr) was studied by calculating the coefficient of variation (CV). The CV was also calculated for the plicometer total skin score and the m-Rodnan's total skin score.
The existence of a relationship between plicometer total skin score and percentages of VC and DLCO reduction in each patient was studied by drawing a regression line for non-linear measures.
All statistical evaluations were performed by using GraphPad Instat TM version 2 and GraphPad Prism TM version 2 software. 
RESULTS
Analysis of healthy skin through the plicometer
The mean, .., ..., median, 95% confidence level and ... of plica thickness values of nine healthy skin areas were calculated separately for 100 male and 100 female individuals (Table IIIa and b, respectively). As expected, different values were observed in the two populations in relationship to the examined skin area. Notably, mean values of plica thickness in all cutaneous regions (and in both populations) are close to median values and show narrow confidence levels.
Two cut-off values (one for male and one for female) were established for each skin area as the mean − 2 ..
Distribution and frequency versus a cut-off of healthy and SSc plicometer skin test values
Plica thickness values of each skin area, derived from plicometer skin test application to both healthy and SSc individuals (separately for male and female), were analysed by Fisher's exact test to verify their distribution compared to each cut-off. A statistically significant difference between plicometer skin test values obtained from healthy and SSc individuals was observed for each skin area (P Q 0.01). The same degree of statistical significance was registered for males and females.
Accuracy of plicometer skin test
In order to evaluate the accuracy of the plicometer skin test, we calculated the sensitivity, specificity, efficiency, PPV and NPV of the plica thickness measurements in both healthy individuals and SSc patients (Table IV) . A wide range of sensitivity values (from 52.6 to 100%) resulted from the analysis of the different skin areas, independently of the observer who performed the measurements. High values of specificity (ranging from 95 to 99%) were found in all examined skin areas. The fact that sensitivity values were generally lower than corresponding specificity values is a consequence of the inclusion in the analysed cases of three patients affected by SSc sine scleroderma who can be considered as three false-negative cases.
PPV, which ranged from 52.4 to 90.5%, were close to sensitivity values. This result reflects the dependency of both parameters on the number of real positive cases and the paucity of both false-negative and false-positive cases. NPV, which ranged from 95.5 to 100%, were close to specificity values, due to the dependency of both parameters on the number of real negative cases.
Reproducibility of the plicometer skin test
To analyse the reproducibility of the plicometer skin test, we calculated the CV of plica thickness measurements performed by six clinicians blinded to each other's readings on the same six healthy and six SSc subjects. Low values of CV were found, as shown in Table Va To compare the reproducibility of the plicometer total skin score and m-Rodnan's total skin score, both methods were applied on five SSc patients by six physicians. For each patient, the mean, .. and CV of 
Analysis of regression between plicometer total skin score and percentages of VC and DLCO reduction
To verify the existence of any relationship between the degrees of skin and visceral involvement, we performed linear regression analysis between the plicometer total skin score and the percentages of VC and DLCO reduction in each SSc patient. The slope of both lines showed a statistically significant difference from zero (P Q 0.01) (Figs 2 and 3 ).
DISCUSSION
The results of our study point out the feasibility, sensitivity, specificity and reproducibility of a new method of investigation and quantification of skin involvement in SSc patients based on the utilization of the plicometer, a medical tool which offers numerical and precise measurements of cutaneous plica thickness. Skin evaluation by plicometer is suggested as a useful parameter for the follow-up of SSc patients.
The most recent and accepted criteria for the classification of SSc patients with scleroderma subdivide them into two clinical categories, diffuse and limited SSc, on the basis of the features of cutaneous and visceral involvement [1] . In particular, the former is characterized by centripetal spreading of cutaneous involvement from hands to forearms, upper arms, shoulders, face, chest, back, abdomen and legs. This phenomenon occurs over a time ranging from a few months to 2-3 yr, and is accompanied by multiple and severe visceral involvement. Although the prognosis of untreated diffuse disease is poor, after the peak period been conceived as a strictly diagnostic tool, but as a method for the staging and follow-up of these patients. Thus, the absence of a positive plicometer skin test the first time the patient is examined does not exclude, per se, the diagnosis of SSc. However, it has to be underlined that the statistical analysis by Fisher's exact test of the distribution of cutaneous plica thickness values in healthy and SSc subjects, as compared to a cut-off (considered as the mean − 2 .. of plica thickness values in healthy individuals for each skin area), clearly separated the two populations. This result is further supported by the calculation of the specificity of plicometer test results, which (mainly in four skin areas: hand, forearm, arm and foot) was extremely elevated (98-99%). On the basis of these results, the finding of lowered plica thickness values by plicometer analysis strongly suggests the presence of scleroderma. On the contrary, the high negative predictive values observed allow us to rule out the hypothesis of skin involvement in the cases of plicometer skin test values that exceed the cut-off.
In order to evaluate whether observer variability can affect the reproducibility of plica thickness measures by plicometer, six different clinicians independently analysed cutaneous plica thickness of two healthy and two SSc individuals (one male and one female). Means, .. and CV of measures were calculated for each skin area and for each subject. Extremely low values of both .. and CV were found, thus indicating a high reproducibility of plica analysis by plicometer. As one of the main aims of plicometer testing would be to follow up scleroderma lesions, we set an arbitrary skin score on the basis of plica measurements. Then, six clinicians independently calculated the total skin score of five SSc patients first by utilizing m-Rodnan's technique and then by using the plicometer. The aim was to compare the reproducibility of both techniques. The plicometer total skin score showed lower CV than m-Rodnan's total skin score, as expected, due to the fact that plicometer measurements are quantitative and objective. The accuracy in monitoring scleroderma lesions with this total skin score and its prognostic capacity are under investigation. However, the fact that it has been possible to identify a linear regression between the plicometer total skin score and pulmonary involvement (assessed by the percentages of VC and DLCO reduction) suggests that plicometer skin score monitoring of SSc patients could be of clinical utility from a prognostic viewpoint. Moreover, this observation further underlines the correlation existing between skin lesion progression and internal organ involvement [2] [3] [4] .
In conclusion, we now propose a new technique to evaluate the extension and spreading of skin lesions in SSc patients that offers a high level of specificity and reproducibility. Studies have already been undertaken to determine whether this new method, in association with clinical, biological (serum concentration of autoantibodies, endothelin-1, adhesion molecules such as VCAM and ICAM-1, cytokines such as IL-6 and TGFb, PDGF, TNFa or their receptor such as IL-2-R, the disease spontaneously improves or arrests [5, 14, 15] . Skin lesions of limited SSc are restricted to the fingers, hands, forearms and face. The disease is characterized by a slow (even 10 yr or more) but continuous worsening and is associated with a high risk of pulmonary hypertension and the spreading of gut disease [14, 15] . Although both the extension and the rate of disease progression differ between diffuse and limited forms of SSc, the spreading of cutaneous lesions in both forms correlates with internal organ involvement, thus representing a sensitive index of disease activity and progression [2] [3] [4] . Although semiquantitative techniques for evaluating skin lesion extension and spreading were first introduced in 1968 (Rodnan's technique and, afterwards, m-Rodnan's technique) [6] [7] [8] , consolidated experiences of clinicians agree on the limited reproducibility of these methods due to observer variability [2, 5, 9] . The plicometer is a cheap and handy medical tool that allows exact (quantitative) measurements of cutaneous plica. Thus, it provides numerical values that are comparable over time and not significantly influenced by the operator. Using a plicometer, we measured the plica of nine body skin areas, which are potential targets of scleroderma, in 200 healthy individuals and identified a minimum normal value for each of them. Male and female plica thickness values of each cutaneous area were calculated separately. Different ranges of normality were obtained for male and female subjects. However, in both groups, the mean of each measurement bordered the median value and showed narrow confidence levels (mean 2 2 ...), thus pointing out the Gaussian distribution of normal male and female populations. The analysis of plica thickness by plicometer was also carried out in 13 patients affected by diffuse SSc, in three patients with limited SSc and in three patients with SSc sine scleroderma. In this study, we decided to include these latter three patients, who did not show any skin alterations at the time of observation, in order to achieve a realistic measurement of the sensitivity and specificity of plicometer analysis. In fact, although the presence of these false-negative cases reduced the sensitivity of the analysis, it provided sensitivity values (ranging from 52 to 100% in relationship to the skin area studied) that can be realistically expected due to the pleomorphism of skin lesion patterns in SSc patients. Moreover, plicometer skin analysis has not procollagen peptides) [16] and instrumental parameters, might allow a better definition of prognosis and more precise follow-up of SSc patients. This last point is of great interest since there are no consolidated therapies for SSc and the experimental ones (immunosuppressive, such as cyclosporin A, cyclophosphamide, methotrexate, photopheresis, -penicillamine, interferon; or vascular, such as iloprost, anticoagulation and endothelin-1 antagonists) need precise monitoring of the disease to be able to ascertain their efficacy.
